Kratom can be habit-forming, particularly with frequent daily use. Its active compounds interact with opioid receptors in the brain, and regular users can develop tolerance, withdrawal symptoms, and patterns consistent with substance use disorder. That said, the dependence potential is notably lower than that of traditional opioids like morphine or heroin, and most people who do experience withdrawal describe it as mild and manageable.
How Kratom Acts on the Brain
Kratom contains dozens of alkaloids, but two drive most of its effects: mitragynine, the most abundant, and 7-hydroxymitragynine, which is present in much smaller quantities but far more potent. Both bind to the same opioid receptors that morphine and other painkillers target, though they do so differently.
Mitragynine has relatively low binding affinity at opioid receptors and actually functions as an antagonist (a blocker) at the main opioid receptor rather than activating it. 7-hydroxymitragynine binds about nine times more strongly and acts as a partial agonist, meaning it activates the receptor but only to about 41% of its maximum capacity. For comparison, morphine is a full agonist. This partial activation is a key reason kratom produces milder effects and weaker dependence than conventional opioids.
Mitragynine also interacts with other receptor systems in the brain, including those involved in adrenaline signaling. This dual action helps explain why kratom feels stimulating at low doses and sedating at higher ones, and why its dependence profile doesn’t map neatly onto classic opioids.
Dependence Risk by Dose and Frequency
Not everyone who uses kratom develops dependence. The biggest predictor isn’t how much you take per dose but how often you take it. Research published in Drug and Alcohol Dependence found that dose frequency was more strongly linked to withdrawal symptoms and signs of problematic use than the amount consumed in a single sitting. People dosing more than six times per day were the most likely to report severe withdrawal. Studies of chronic users in Malaysia found a similar threshold: three or more servings daily was associated with greater withdrawal severity.
Withdrawal has typically been reported among people consuming more than 3 grams of leaf material multiple times per day over an extended period, likely exceeding 300 milligrams of mitragynine daily. At lower, less frequent use, the risk of physical dependence drops considerably.
What Withdrawal Feels Like
Kratom withdrawal shares symptoms with both opioid and stimulant withdrawal. Physical symptoms include runny nose, muscle aches, and diarrhea. Psychological symptoms tend to involve lethargy, depressed mood, and anxiety. The overlap with opioid withdrawal is real but the intensity is different. In animal studies, stopping kratom after chronic exposure did not produce the significant spontaneous withdrawal signs seen with morphine. When withdrawal was chemically triggered, the effects were weaker and shorter-lived in kratom-treated animals compared to morphine-treated ones.
Surveys of U.S. kratom users paint a consistent picture: for those who do experience withdrawal, most find it mild, tolerable, and something they can manage on their own without medical intervention.
How Kratom Compares to Traditional Opioids
Multiple lines of evidence suggest kratom’s habit-forming potential is substantially lower than that of drugs like morphine or heroin. In self-administration studies, where animals can press a lever to receive a drug, rats given access to mitragynine pressed the lever at the same rate as rats given saltwater, a sign of no rewarding effect. By contrast, morphine reliably drives compulsive self-administration. Even more telling, pretreating rats with mitragynine actually reduced how much morphine and heroin they self-administered.
Brain reward studies reinforce this. Neither mitragynine nor 7-hydroxymitragynine produced the brain-stimulating reward effects that morphine does. The overall research picture points to relatively low abuse potential compared to opioids, stimulants, and other commonly abused substances. The potential for physical dependence is not absent, but it is meaningfully weaker.
Prevalence of Problematic Use
A Johns Hopkins study assessed over 2,000 kratom consumers using the same diagnostic framework (DSM-5 criteria) applied to other substance use disorders. About 25.5% of participants met criteria for what researchers termed “kratom use disorder.” The two most common symptoms were tolerance, reported by 81% of those who qualified, and withdrawal, reported by 68%. These numbers deserve context: tolerance and withdrawal are the two criteria most tied to regular use of any substance affecting the brain, and meeting the threshold required additional symptoms like using more than intended or continuing use despite negative consequences.
What the FDA Says
The FDA has warned consumers against using kratom, citing risks including liver toxicity, seizures, and substance use disorder. The agency notes that some individuals have met clinical criteria for substance use disorder after kratom use, including taking it longer or in greater amounts than intended, experiencing cravings, developing tolerance, and going through withdrawal. Kratom is not approved as a drug, dietary supplement, or food additive in the United States. However, the FDA also acknowledges that a well-designed human abuse potential study has not yet been completed, meaning the full picture of kratom’s abuse liability remains incomplete.
Managing Kratom Dependence
No official treatment guidelines exist specifically for kratom dependence. In clinical practice, some providers have used the same medications prescribed for opioid use disorder. A case series review found that the medication commonly used for opioid addiction was effective for kratom-dependent patients, with the required dose correlating to how much kratom the person had been using. People consuming under 20 grams daily needed lower doses, while those using over 40 grams daily required higher amounts.
For people with mild dependence, gradual tapering (slowly reducing the amount and frequency of kratom use) is a common self-managed approach. Because frequency of dosing is the strongest driver of dependence, spacing out doses and reducing how many times per day you use kratom may be more impactful than simply cutting the amount per dose.
Product Purity as a Hidden Variable
Because kratom is sold as an unregulated product, what’s actually in a given powder or capsule can vary widely. Some products have been found to contain synthetic drugs or contaminants that could alter dependence risk in unpredictable ways. The American Kratom Association has developed voluntary manufacturing standards that include testing every production lot for synthetic drugs, heavy metals, chemical contaminants, and harmful microorganisms. Products from vendors that follow these standards are more likely to contain only kratom, but participation is voluntary, and many sellers operate outside any quality framework.